ArticleJournal of nanobiotechnology2026
Ultrasound and ROS-responsive nanodroplets inhibit TCA cycle in hepatocellular carcinoma.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Abnormal energy metabolism patterns are common characteristics of various tumor cells, including hepatocellular carcinoma cells (HCC). HCC undergo metabolic reprogramming, upregulating the tricarboxylic acid (TCA) cycle and mitochondrial respiration to provide energy. Based on this, we constructed a novel reactive oxygen species (ROS)- and ultrasound-responsive nanodroplet (named sGTND), which were loaded with glucose-6-phosphate dehydrogenase (G6PD) siRNA and modified with glycyrrhetinic acid (GA) via GTC polymer. These sGTNDs have a particle size of approximately 300 nm, exhibit excellent biocompatibility and contrast-enhanced ultrasound imaging. By recognizing GA receptors, sGTNDs can be specifically targeted and enriched within HCC. Under the combined effect of ultrasound-targeted microbubble destruction (UTMD), sGTNDs release GA to activate the nuclear factor erythroid 2-related factor 2 (NRF2) while simultaneously releasing siRNA to inhibit G6PD. This dual action synergistically inhibits the TCA cycle, resulting in an antitumor efficacy of up to 95.1%, which is significantly higher than that observed in the control groups. Thus, the combination of sGTND and UTMD can effectively inhibit the TCA cycle through NRF2 activation and G6PD inhibition, which represents a promising therapeutic approach for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.